Condition: Myelodysplastic Syndrome (MDS) · Sponsor: Taiho Pharmaceutical Co., Ltd.
The purpose of this study is to identify the doses of the oral azacitidine formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2
This description comes directly from the study's public registry record.
Drug Information Center · +81-3-3294-4527 · ke-watanabe@taiho.co.jp
Always discuss trial participation with your own doctor first.
| Nippon Medical School Hospital | Bunkyō City, Japan | Recruiting |
| Fukushima Medical University Hospital | Fukushima, Japan | Recruiting |
| Saitama Medical University Hospital | Iruma, Japan | Recruiting |
| University Hospital, Kyoto Prefectural University of Medicine | Kyoto, Japan | Recruiting |
| Nagasaki University Hospital | Nagasaki, Japan | Recruiting |
| Osaka City General Hospital | Osaka, Japan | Recruiting |
| Kindai University Hospital | Sakai, Japan | Recruiting |
| NTT Medical Center Tokyo | Shinagawa-Ku, Japan | Recruiting |
| Tokyo Medical University Hospital | Shinjuku-Ku, Japan | Recruiting |
| Yamagata University Hospital | Yamagata, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04608110